Cooperative Agreement U01CA320916
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $718K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10032, USA
Similar Awards
- The National Cancer Institute awarded the University of Southern California $681,676 on April 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct translational epidemiological and mechanistic research linking per- and polyfluoroalkyl substances (PFAS) exposure to hepatocellular carcinoma and metabolic dysfunction-associated steatotic liver disease. The award funds a five-year project (April 1, 2026 through March 31, 2031) performed in Los Angeles,...
- The National Cancer Institute awarded The Johns Hopkins University $645,435 on September 2, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a multimodal blood-based classifier for early hepatocellular carcinoma (HCC) detection. The research integrates genome-wide methods—fragmentomics (DELFI), repeat landscapes (ARTEMIS), methylomics, mutational signatures (GEMINI), and plasma proteomics—into a single machine learning classifier to improve HCC...
- The National Cancer Institute awarded the University of North Carolina at Chapel Hill $399,829 on May 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and implement a population-based hepatocellular carcinoma surveillance registry and assess feasibility for identifying at-risk patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The award funds research to establish tools for a population-based HCC surveillance registry that...
- The National Cancer Institute awarded the University of Illinois $412,249 on June 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop precision liver cancer models through CRISPR editing of primary human hepatocytes. The award funds development of a versatile platform to recapitulate hepatocellular carcinoma (HCC) molecular heterogeneity by introducing driver gene mutations commonly observed in human HCC into normal primary human hepatocytes, addressing critical...
- The National Cancer Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Trustees of Columbia University in the City of New York $630,089 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research to characterize the molecular mechanisms by which the DNA translocase SMARCAL1 suppresses anti-tumor immune responses and to identify other DNA damage response factors that function analogously to...
- The National Cancer Institute awarded the University of Texas Health Science Center at Houston $401,115 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the molecular mechanisms governing the progression from metabolic dysfunction-associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). The funded research examines the role of SIRT3, a NAD+-dependent deacetylase that regulates mitochondrial function, in preventing disease progression. The...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $701,574 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate APOBEC3-induced mutagenesis in cancer development and therapy resistance. The funded research develops experimental and bioinformatics methods to track de novo generation of specific mutational signatures (SBS2 and SBS13) induced by individual...
- The National Cancer Institute awarded The Rockefeller University $559,596 on July 1, 2026, for research identifying metabolic vulnerabilities in liver cancer under the Cancer Biology Research program (CFDA 93.396). The funded research characterizes mitochondrial metabolites that drive hepatocellular carcinoma and other primary liver cancers through a rapid organelle immunopurification technique (MITO-IP) coupled with liquid chromatography–mass spectrometry. Preliminary work identified marked...
- The National Cancer Institute awarded the University of Southern California $699,303 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify pre-diagnostic epigenetic biomarkers of colorectal cancer risk and understand epigenetic mechanisms of lifestyle and genetic CRC risk factors across multiple U.S. populations. The research will conduct a nested case-control study of 1,500 colorectal cancer cases and 1,500 matched controls drawn from the...
- The National Cancer Institute awarded Virginia Commonwealth University $634,062 on June 5, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate atypical sphingolipids in hepatocellular carcinoma (HCC) metabolism and identify SPTLC3 as a potential therapeutic target. The award funds three research aims examining how the SPTLC3 enzyme subunit regulates metabolic pathways in liver cancer cells. Aim 1 determines the scope of SPTLC3-mediated metabolic regulation in...